Neuronetics, Inc. (NASDAQ:STIM) EVP Stephen Furlong Sells 193,460 Shares

Neuronetics, Inc. (NASDAQ:STIM) EVP Stephen Furlong sold 193,460 shares of the company’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $4.27, for a total transaction of $826,074.20. Following the completion of the transaction, the executive vice president now owns 416,593 shares in the company, valued at approximately $1,778,852.11. This trade represents a 31.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Stephen Furlong also recently made the following trade(s):

• On Tuesday, March 4th, Stephen Furlong sold 1,867 shares of Neuronetics stock. The stock was sold at an average price of $4.48, for a total transaction of $8,364.16.
• On Friday, February 14th, Stephen Furlong sold 17,307 shares of Neuronetics stock. The stock was sold at an average price of $4.11, for a total transaction of $71,131.77.

Neuronetics Stock Performance

Shares of NASDAQ:STIM opened at $4.30 on Friday. The company’s 50 day moving average price is $4.20 and its two-hundred day moving average price is $2.91. Neuronetics, Inc. has a 12-month low of $0.52 and a 12-month high of $5.92. The firm has a market cap of $283.03 million, a PE ratio of -3.50 and a beta of 1.92. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90.

Neuronetics (NASDAQ:STIM) last announced its earnings results on Tuesday, May 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). The business had revenue of $31.98 million for the quarter, compared to analyst estimates of $29.07 million. Neuronetics had a negative return on equity of 141.24% and a negative net margin of 50.09%. Equities research analysts predict that Neuronetics, Inc. will post -1.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group increased their target price on shares of Neuronetics from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th.

Institutional Trading of Neuronetics

Large investors have recently made changes to their positions in the company. Larson Financial Group LLC acquired a new stake in shares of Neuronetics during the 1st quarter worth approximately $25,000. KPP Advisory Services LLC acquired a new stake in shares of Neuronetics during the 1st quarter worth approximately $37,000. FORA Capital LLC acquired a new stake in shares of Neuronetics during the 1st quarter worth approximately $42,000. National Bank of Canada FI boosted its position in shares of Neuronetics by 19,491.5% during the 1st quarter. National Bank of Canada FI now owns 11,559 shares of the company’s stock worth $42,000 after acquiring an additional 11,500 shares in the last quarter. Finally, Presidio Capital Management LLC acquired a new stake in shares of Neuronetics during the 1st quarter worth approximately $44,000. Institutional investors and hedge funds own 53.59% of the company’s stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.